Oxford Biomedica plc Provides Earnings Guidance for the Year Ended December 31, 2023 and for the Fiscal Year 2024
Projected fiscal year 2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes.